MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jhep.2023.10.030

Медицинская библиотека · Journal of hepatology · 2023

JAK1 promotes HDV replication and is a potential target for antiviral therapy.

Heuschkel Margaux J, Bach Charlotte, Meiss-Heydmann Laura, Gerges Emma, Felli Emanuele, Giannone Fabio, Pessaux Patrick, Schuster Catherine, Lucifora Julie, Baumert Thomas F, Verrier Eloi R

СтатьяПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND & AIMS: Chronic co-infection with HBV and HDV leads to the most aggressive form of chronic viral hepatitis. To date, no treatment induces efficient viral clearance, and a better characterization of virus-host interactions is required to develop new therapeutic strategies.

METHODS

Using loss-of-function strategies, we validated the unexpected proviral activity of Janus kinase 1 (JAK1) - a key player in innate immunity - in the HDV life cycle and determined its mechanism of action on HDV through various functional analyses including co-immunoprecipitation assays.

RESULTS

We confirmed the key role of JAK1 kinase activity in HDV infection. Moreover, our results suggest that JAK1 inhibition is associated with a modulation of ERK1/2 activation and S-HDAg phosphorylation, which is crucial for viral replication. Finally, we showed that FDA-approved JAK1-specific inhibitors are efficient antivirals in relevant in vitro models including primary human hepatocytes.

CONCLUSIONS

Taken together, we uncovered JAK1 as a key host factor for HDV replication and a potential target for new antiviral treatment.

IMPACT AND IMPLICATIONS: Chronic hepatitis D is the most aggressive form of chronic viral hepatitis. As no curative treatment is currently available, new therapeutic strategies based on host-targeting agents are urgently needed. Here, using loss-of-function strategies, we uncover an unexpected interaction between JAK1, a major player in the innate antiviral response, and HDV infection. We demonstrated that JAK1 kinase activity is crucial for both the phosphorylation of the delta antigen and the replication of the virus. By demonstrating the antiviral potential of several FDA-approved JAK1 inhibitors, our results could pave the way for the development of innovative therapeutic strategies to tackle this global health threat.

Для цитирования: Heuschkel Margaux J, Bach Charlotte, Meiss-Heydmann Laura, Gerges Emma, Felli Emanuele, Giannone Fabio, Pessaux Patrick, Schuster Catherine, Lucifora Julie, Baumert Thomas F, Verrier Eloi R. JAK1 promotes HDV replication and is a potential target for antiviral therapy.. Journal of hepatology. 2023. DOI: 10.1016/j.jhep.2023.10.030.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.